Nutraferon CT-Pride Tablet contains Cinitapride 1mg, a prokinetic agent primarily indicated for the management of gastrointestinal motility disorders. Cinitapride acts as a selective serotonin 5-HT4 receptor agonist and 5-HT1 receptor antagonist, facilitating enhanced gastric emptying and improved esophageal and intestinal motility. This pharmacological profile makes Nutraferon CT-Pride effective in treating conditions such as gastroesophageal reflux disease (GERD), functional dyspepsia, and gastroparesis. The medication works by stimulating acetylcholine release in the enteric nervous system, thereby promoting coordinated contractions of the gastrointestinal smooth muscle. Nutraferon CT-Pride is generally well tolerated, with adverse effects being mild and infrequent; these may include headache, dizziness, and diarrhea. It is contraindicated in patients with known hypersensitivity to Cinitapride or any of its excipients, as well as in individuals with intestinal obstruction or perforation. Caution is advised when administering to patients with a history of cardiac arrhythmias or those concurrently using other serotonergic agents. Dosage should be individualized based on clinical response and tolerability, typically administered orally before meals. Nutraferon CT-Pride offers a valuable therapeutic option for improving gastrointestinal motility and alleviating associated symptoms, thereby enhancing patient quality of life.